ESMO Breast 2024 | Exploring extended adjuvant chemotherapy for luminal cancers

Masakazu Toi • 17 May 2024

ESMO Breast 2024

Breast Cancer

Masakazu Toi, MD, PhD, Kyoto University, Kyoto, Japan, discusses the role of extended adjuvant chemotherapy for patients with intermediate or high-risk luminal cancers. With multiple treatment options now available, including CDK4/6 inhibitors and PARP inhibitors, extended chemotherapy in the adjuvant setting, particularly the use of oral fluoropyrimidines approved in Asia, offers new possibilities. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.